KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $2.3 billion.

  • Biogen's Operating Expenses rose 796.04% to $2.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $8.3 billion, marking a year-over-year increase of 726.14%. This contributed to the annual value of $8.3 billion for FY2025, which is 726.14% up from last year.
  • Per Biogen's latest filing, its Operating Expenses stood at $2.3 billion for Q4 2025, which was up 796.04% from $2.0 billion recorded in Q3 2025.
  • Over the past 5 years, Biogen's Operating Expenses peaked at $2.7 billion during Q3 2023, and registered a low of $1.1 billion during Q3 2022.
  • Moreover, its 5-year median value for Operating Expenses was $2.0 billion (2023), whereas its average is $2.0 billion.
  • As far as peak fluctuations go, Biogen's Operating Expenses tumbled by 5428.09% in 2022, and later soared by 13487.78% in 2023.
  • Quarter analysis of 5 years shows Biogen's Operating Expenses stood at $2.3 billion in 2021, then decreased by 16.69% to $1.9 billion in 2022, then increased by 7.96% to $2.1 billion in 2023, then increased by 3.27% to $2.2 billion in 2024, then rose by 7.96% to $2.3 billion in 2025.
  • Its Operating Expenses stands at $2.3 billion for Q4 2025, versus $2.0 billion for Q3 2025 and $1.9 billion for Q2 2025.